Corvus Pharmaceuticals (CRVS) Rating Increased to Sell at ValuEngine

ValuEngine upgraded shares of Corvus Pharmaceuticals (NASDAQ:CRVS) from a strong sell rating to a sell rating in a report published on Wednesday morning.

Other analysts also recently issued research reports about the company. Zacks Investment Research downgraded Corvus Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, January 5th. Cowen reiterated a buy rating on shares of Corvus Pharmaceuticals in a research note on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Corvus Pharmaceuticals presently has a consensus rating of Hold and an average price target of $18.67.

How to Become a New Pot Stock Millionaire

Corvus Pharmaceuticals stock opened at $10.12 on Wednesday. Corvus Pharmaceuticals has a fifty-two week low of $7.42 and a fifty-two week high of $17.64.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Thursday, March 1st. The company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.18. sell-side analysts anticipate that Corvus Pharmaceuticals will post -3.15 earnings per share for the current year.

In related news, major shareholder Adams Street Partners Llc bought 588,235 shares of the stock in a transaction dated Monday, March 12th. The shares were purchased at an average price of $8.50 per share, for a total transaction of $4,999,997.50. Following the completion of the purchase, the insider now directly owns 4,420,516 shares of the company’s stock, valued at $37,574,386. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Richard A. Md Miller bought 100,000 shares of the stock in a transaction dated Monday, March 12th. The stock was bought at an average price of $8.50 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. 46.40% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP purchased a new stake in shares of Corvus Pharmaceuticals in the second quarter worth about $320,000. SG Americas Securities LLC purchased a new stake in shares of Corvus Pharmaceuticals in the fourth quarter worth about $150,000. Northern Trust Corp boosted its stake in shares of Corvus Pharmaceuticals by 97.6% in the second quarter. Northern Trust Corp now owns 86,525 shares of the company’s stock worth $1,047,000 after buying an additional 42,739 shares during the last quarter. Spark Investment Management LLC purchased a new stake in shares of Corvus Pharmaceuticals in the fourth quarter worth about $295,000. Finally, California State Teachers Retirement System boosted its stake in shares of Corvus Pharmaceuticals by 121.2% in the second quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock worth $181,000 after buying an additional 8,200 shares during the last quarter. Hedge funds and other institutional investors own 82.71% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Corvus Pharmaceuticals (CRVS) Rating Increased to Sell at ValuEngine” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/corvus-pharmaceuticals-crvs-rating-increased-to-sell-at-valuengine.html.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply